TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post-Mortem Temporal Cortices

Brain Pathology

Volumn 25, Issue 4, 2015, Pages 469-480

  Lue, Lih Fen ^a   Schmitz, Christopher T ^a   Serrano, Geidy ^a   Sue, Lucia I ^a   Beach, Thomas G ^a   Walker, Douglas G ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

amyloid; brain; human; microglia; tau; TREM2

Indexed keywords

CASPASE 3; IMMUNOGLOBULIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TRIGGERING RECEPTOR EXPRESSED BY MYELOID CELLS 2 PROTEIN; UNCLASSIFIED DRUG; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TREM2 PROTEIN, HUMAN; TYROBP PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOPSY; BRAIN REGION; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROGLIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; TEMPORAL CORTEX; TISSUE SECTION; WESTERN BLOTTING; ANALYSIS OF VARIANCE; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEURODEGENERATIVE DISEASES; NONPARAMETRIC TEST; PATHOLOGY; PHYSIOLOGY; POSTMORTEM CHANGE; SINGLE NUCLEOTIDE POLYMORPHISM; TEMPORAL LOBE; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CASPASE 3; FEMALE; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICROGLIA; NEURODEGENERATIVE DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMORTEM CHANGES; RECEPTORS, IMMUNOLOGIC; STATISTICS, NONPARAMETRIC; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TEMPORAL LOBE;

EID: 84931401474     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12190     Document Type: Article

References (53)

1. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, et al (2008) The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank 9: 229-245.
2. Bianchin MM, Capella HM, Chaves DL, Steindel M, Grisard EC, Ganev GG, et al (2004) Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy-PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol Neurobiol 24: 1-24.
3. Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, et al (2013) Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging 35 (4):p 934.e7-934.e10.
4. Bouchon A, Dietrich J, Colonna M, (2000) Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 164: 4991-4995.
5. Bouchon A, Hernandez-Munain C, Cella M, Colonna M, (2001) A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 194: 1111-1122.
6. Braak H, Braak E, (1997) Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 18: S85-S88.
7. Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, et al (2014) TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 71: 449-453.
8. Colonna M, (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3: 445-453.
9. Crotti TN, Dharmapatni AA, Alias E, Zannettino AC, Smith MD, Haynes DR, (2012) The immunoreceptor tyrosine-based activation motif (ITAM)-related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Res Ther 14: R245.
10. Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, et al (2013) GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron 78: 256-268.
11. Cuyvers E, Bettens K, Philtjens S, Van LT, Gijselinck I, van der Zee J, et al (2014) Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 35: 726.e11-726.e19.
12. Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, Deller T, (2008) TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56: 1438-1447.
13. Gehrmann J, (1996) Microglia: a sensor to threats in the nervous system? Res Virol 147: 79-88.
14. Giraldo M, Lopera F, Siniard AL, Corneveaux JJ, Schrauwen I, Carvajal J, et al (2013) Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol Aging 34: 2077-2078.
15. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368: 117-127.
16. Hamerman JA, Ni M, Killebrew JR, Chu CL, Lowell CA, (2009) The expanding roles of ITAM adapters FcRgamma and DAP12 in myeloid cells. Immunol Rev 232: 42-58.
17. Hickman SE, El KJ, (2014) TREM2 and the neuroimmunology of Alzheimer's disease. Biochem Pharmacol 88: 495-498.
18. Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE, (2009) A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109: 1144-1156.
19. Ivashkiv LB, (2009) Cross-regulation of signaling by ITAM-associated receptors. Nat Immunol 10: 340-347.
20. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107-116.
21. Kaneko M, Sano K, Nakayama J, Amano N, (2010) Nasu-Hakola disease: the first case reported by Nasu and review. Neuropathology 30: 463-470.
22. Kiialainen A, Hovanes K, Paloneva J, Kopra O, Peltonen L, (2005) Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. Neurobiol Dis 18: 314-322.
23. Kleinberger G, Yamanishi Y, Suárez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6: 243ra86.
24. Klunemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, et al (2005) The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology 64: 1502-1507.
25. Linnartz B, Neumann H, (2013) Microglial activatory (immunoreceptor tyrosine-based activation motif)- and inhibitory (immunoreceptor tyrosine-based inhibition motif)-signaling receptors for recognition of the neuronal glycocalyx. Glia 61: 37-46.
26. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, et al (2001) Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171: 29-45.
27. Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, et al (2012) Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol 22: 745-756.
28. Melchior B, Puntambekar SS, Carson MJ, (2006) Microglia and the control of autoreactive T cell responses. Neurochem Int 49: 145-153.
29. Melchior B, Garcia AE, Hsiung BK, Lo KM, Doose JM, Thrash JC, et al (2010) Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro 2: e00037.
30. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486.
31. Moses GS, Jensen MD, Lue LF, Walker DG, Sun AY, Simonyi A, Sun GY, (2006) Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. J Neuroinflammation 3: 28.
32. N'Diaye EN, Branda CS, Branda SS, Nevarez L, Colonna M, Lowell C, et al (2009) TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J Cell Biol 184: 215-223.
33. Neumann H, Takahashi K, (2007) Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol 184: 92-99.
34. Paloneva J, Kestila M, Wu J, Salminen A, Bohling T, Ruotsalainen V, et al (2000) Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet 25: 357-361.
35. Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, et al (2002) Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 71: 656-662.
36. Paradowska-Gorycka A, Jurkowska M, (2013) Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12. Hum Immunol 74: 730-737.
37. Piccio L, Buonsanti C, Mariani M, Cella M, Gilfillan S, Cross AH, et al (2007) Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol 37: 1290-1301.
38. Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, et al (2008) Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain 131: 3081-3091.
39. Prada I, Ongania GN, Buonsanti C, Panina-Bordignon P, Meldolesi J, (2006) Triggering receptor expressed in myeloid cells 2 (TREM2) trafficking in microglial cells: continuous shuttling to and from the plasma membrane regulated by cell stimulation. Neuroscience 140: 1139-1148.
40. Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, et al (2013) TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener 8: 19.
41. Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, et al (2002) Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem 83: 1309-1320.
42. Sessa G, Podini P, Mariani M, Meroni A, Spreafico R, Sinigaglia F, et al (2004) Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur J Neurosci 20: 2617-2628.
43. Stefano L, Racchetti G, Bianco F, Passini N, Gupta RS, Panina BP, Meldolesi J, (2009) The surface-exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor. J Neurochem 110: 284-294.
44. Takahashi K, Rochford CD, Neumann H, (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201: 647-657.
45. Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H, (2007) TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med 4: e124.
46. Tessarz AS, Cerwenka A, (2008) The TREM-1/DAP12 pathway. Immunol Lett 116: 111-116.
47. Thrash JC, Torbett BE, Carson MJ, (2009) Developmental regulation of TREM2 and DAP12 expression in the murine CNS: implications for Nasu-Hakola disease. Neurochem Res 34: 38-45.
48. Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, et al (2014) Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener 9: 20.
49. Verloes A, Maquet P, Sadzot B, Vivario M, Thiry A, Franck G, (1997) Nasu-Hakola syndrome: polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia. J Med Genet 34: 753-757.
50. Wakselman S, Bechade C, Roumier A, Bernard D, Triller A, Bessis A, (2008) Developmental neuronal death in hippocampus requires the microglial CD11b integrin and DAP12 immunoreceptor. J Neurosci 28: 8138-8143.
51. Wang L, Gordon RA, Huynh L, Su X, Park Min KH, Han J, et al (2010) Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins. Immunity 32: 518-530.
52. Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J, (2013) Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-dependent intramembranous cleavage. J Biol Chem 288: 33027-33036.
53. The National Institute on Aging and Reagan Institute Working group (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18: S1-S2.